Shineco, Inc. (SISI)
USD 2.12
(-4.07%)
USD 2.12
(-4.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -26.55 Million USD | -228.05% |
| 2023 | -8.09 Million USD | 60.73% |
| 2022 | -6.19 Million USD | 7.45% |
| 2021 | -21.18 Million USD | -846.13% |
| 2020 | -4.57 Million USD | -296.07% |
| 2019 | 906.94 Thousand USD | -90.87% |
| 2018 | 9.96 Million USD | 51.14% |
| 2017 | 8.02 Million USD | -2.33% |
| 2016 | 8.21 Million USD | 12.29% |
| 2015 | 7.31 Million USD | -6.33% |
| 2014 | 7.8 Million USD | 0.61% |
| 2013 | 7.76 Million USD | 0.0% |
| 2006 | 76.03 Thousand USD | -84.38% |
| 2005 | 486.66 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.88 Million USD | 50.63% |
| 2024 Q1 | -2.33 Million USD | 6.13% |
| 2024 Q2 | -3.97 Million USD | -74.06% |
| 2024 Q4 | -4.09 Million USD | -906.7% |
| 2023 Q1 | -1.97 Million USD | 73.02% |
| 2023 Q2 | -2.15 Million USD | -9.39% |
| 2023 Q4 | -1.14 Million USD | 43.28% |
| 2023 Q3 | -2.02 Million USD | 6.17% |
| 2023 FY | - USD | 60.73% |
| 2022 Q2 | -1.47 Million USD | 81.0% |
| 2022 FY | - USD | 7.45% |
| 2022 Q1 | -7.78 Million USD | -992.25% |
| 2022 Q4 | -7.31 Million USD | -215.18% |
| 2022 Q3 | -2.31 Million USD | -56.88% |
| 2021 Q2 | -9.13 Million USD | -1393.56% |
| 2021 Q1 | -611.71 Thousand USD | -521.96% |
| 2021 Q3 | -7.56 Million USD | 17.25% |
| 2021 Q4 | 872.34 Thousand USD | 111.54% |
| 2021 FY | - USD | -846.13% |
| 2020 Q1 | -1.64 Million USD | -286.84% |
| 2020 Q2 | 676.35 Thousand USD | 141.01% |
| 2020 Q3 | -3.4 Million USD | -603.36% |
| 2020 Q4 | 144.96 Thousand USD | 104.26% |
| 2020 FY | - USD | -296.07% |
| 2019 Q4 | 882.66 Thousand USD | 171.39% |
| 2019 Q3 | -1.23 Million USD | -282.41% |
| 2019 FY | - USD | -90.87% |
| 2019 Q1 | 582.89 Thousand USD | -57.31% |
| 2019 Q2 | 677.84 Thousand USD | 16.29% |
| 2018 Q4 | 1.36 Million USD | -66.79% |
| 2018 FY | - USD | 51.14% |
| 2018 Q3 | 4.11 Million USD | 21.35% |
| 2018 Q2 | 3.38 Million USD | 206.77% |
| 2018 Q1 | 1.1 Million USD | -52.43% |
| 2017 Q4 | 2.32 Million USD | 28.11% |
| 2017 Q1 | 1.21 Million USD | -24.62% |
| 2017 Q2 | 2.66 Million USD | 119.19% |
| 2017 Q3 | 1.81 Million USD | -32.11% |
| 2017 FY | - USD | -2.33% |
| 2016 Q3 | 1.54 Million USD | -56.17% |
| 2016 Q1 | 1.68 Million USD | 84.39% |
| 2016 Q4 | 1.61 Million USD | 4.8% |
| 2016 FY | - USD | 12.29% |
| 2016 Q2 | 3.51 Million USD | 109.27% |
| 2015 FY | - USD | -6.33% |
| 2015 Q4 | 911.62 Thousand USD | -49.17% |
| 2015 Q3 | 1.79 Million USD | -38.79% |
| 2015 Q2 | 2.92 Million USD | 74.53% |
| 2015 Q1 | 1.67 Million USD | -20.4% |
| 2014 Q4 | 2.1 Million USD | 90.92% |
| 2014 Q2 | 2.33 Million USD | -0.0% |
| 2014 Q3 | 1.1 Million USD | -52.67% |
| 2014 Q1 | 2.33 Million USD | -19.13% |
| 2014 FY | - USD | 0.61% |
| 2013 Q4 | 2.88 Million USD | 47.99% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | 1.95 Million USD | 0.0% |
| 2007 Q3 | 53.38 Thousand USD | 0.0% |
| 2007 Q1 | 32.61 Thousand USD | 0.0% |
| 2006 Q3 | 76.07 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | -84.38% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | 133.01 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | -157.485% |
| Harrow Health, Inc. | 9.72 Million USD | 373.104% |
| Dynavax Technologies Corporation | 9.66 Million USD | 374.715% |
| Biofrontera Inc. | -18.45 Million USD | -43.9% |
| Cronos Group Inc. | -72.14 Million USD | 63.196% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -486.827% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.129% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 26.407% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 201.096% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -3635.516% |
| Radius Health, Inc. | 38.31 Million USD | 169.313% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -725.921% |
| DURECT Corporation | -24.68 Million USD | -7.575% |
| ProPhase Labs, Inc. | -14.82 Million USD | -79.092% |
| Safety Shot Inc | -12.18 Million USD | -117.92% |
| Phibro Animal Health Corporation | 84.6 Million USD | 131.385% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -1029.468% |
| Alvotech | -484.86 Million USD | 94.523% |
| Assertio Holdings, Inc. | -222.44 Million USD | 88.063% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 127.024% |
| Rockwell Medical, Inc. | -4.69 Million USD | -465.699% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -594.326% |
| Procaps Group S.A. | 104.02 Million USD | 125.526% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 83.284% |
| SCYNEXIS, Inc. | 73.47 Million USD | 136.138% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -2523.905% |
| Viatris Inc. | 3.51 Billion USD | 100.755% |
| OptiNose, Inc. | -15.55 Million USD | -70.732% |
| SIGA Technologies, Inc. | 84.15 Million USD | 131.552% |
| Tilray Brands, Inc. | -72.84 Million USD | 63.546% |
| PetIQ, Inc. | 81.48 Million USD | 132.587% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -594.326% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 106.382% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -576.989% |
| Alimera Sciences, Inc. | 7.27 Million USD | 464.952% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 108.612% |
| Silver Spike Investment Corp. | 7.34 Million USD | 461.765% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -565.403% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 173.697% |
| Journey Medical Corporation | 1.92 Million USD | 1482.296% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -530.454% |
| Alpha Teknova, Inc. | -25.53 Million USD | -3.974% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -58.021% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 3370.186% |
| PainReform Ltd. | -9.56 Million USD | -177.499% |
| Cosmos Health Inc. | -17.06 Million USD | -55.634% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 82.194% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -216.08% |
| Embecta Corp. | 245.4 Million USD | 110.821% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -634.014% |
| Talphera, Inc. | -9.84 Million USD | -169.802% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 116.301% |
| Incannex Healthcare Limited | -18.5 Million USD | -43.504% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -32.566% |
| Procaps Group, S.A. | 104.02 Million USD | 125.526% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 124.29% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 2346.524% |
| Lantheus Holdings, Inc. | 491 Million USD | 105.408% |
| Alvotech | -484.86 Million USD | 94.523% |
| Hempacco Co., Inc. | -12.77 Million USD | -107.887% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 134.262% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 82.31% |
| Kamada Ltd. | 21.53 Million USD | 223.312% |
| Indivior PLC | 66 Million USD | 140.233% |
| Evoke Pharma, Inc. | -7.29 Million USD | -264.137% |
| Flora Growth Corp. | -45.87 Million USD | 42.11% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -32.566% |
| Evolus, Inc. | -41.81 Million USD | 36.489% |
| HUTCHMED (China) Limited | 25.52 Million USD | 204.019% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 110.997% |
| Akanda Corp. | -27.73 Million USD | 4.261% |